Search research articles
Contact Us
Filters
Showing results (181-190 of 206) with videos related to
Page
of 21
Sort By:
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 31, 2017
Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine
|
September 2, 2016
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial
Fernando J Martinez, Klaus F Rabe, Sanjay Sethi, et al.
Respiratory Research
|
August 21, 2019
Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD
Venkataramana K Sidhaye, Janet T Holbrook, Alyce Burke, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 4, 2015
IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Abraham B Roos, Sanjay Sethi, Jake Nikota, et al.
The European Respiratory Journal
|
April 14, 2017
The microbiome in respiratory medicine: current challenges and future perspectives
Rosa Faner, Oriol Sibila, Alvar Agustí, et al.
Respiratory Research
|
September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
Leonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Nature Protocols
|
December 9, 2022
High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation
Shichen Shen, Xue Wang, Xiaoyu Zhu, et al.
BMJ Open
|
July 24, 2025
Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS/AVOIDEX programme
Kirsty Rhodes, Deven Patel, My Linh Duong, et al.
Plos One
|
March 29, 2017
Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
Robert A Wise, Janet T Holbrook, Gerard Criner, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 206) with videos related to
Sort By:
Page
of 21
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 31, 2017
Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine
|
September 2, 2016
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial
Fernando J Martinez, Klaus F Rabe, Sanjay Sethi, et al.
Respiratory Research
|
August 21, 2019
Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD
Venkataramana K Sidhaye, Janet T Holbrook, Alyce Burke, et al.
American Journal of Respiratory and Critical Care Medicine
|
June 4, 2015
IL-17A and the Promotion of Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Abraham B Roos, Sanjay Sethi, Jake Nikota, et al.
The European Respiratory Journal
|
April 14, 2017
The microbiome in respiratory medicine: current challenges and future perspectives
Rosa Faner, Oriol Sibila, Alvar Agustí, et al.
Respiratory Research
|
September 3, 2016
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
Leonardo M Fabbri, Edward M Kerwin, Selwyn Spangenthal, et al.
Nature Protocols
|
December 9, 2022
High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation
Shichen Shen, Xue Wang, Xiaoyu Zhu, et al.
BMJ Open
|
July 24, 2025
Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS/AVOIDEX programme
Kirsty Rhodes, Deven Patel, My Linh Duong, et al.
Plos One
|
March 29, 2017
Correction: Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
Robert A Wise, Janet T Holbrook, Gerard Criner, et al.
Page
of 21